Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27575797 | 0.80 | SLC6A2 (0.54) | SLC6A2TAAR1CYP2D6LMNATRPA1 | |
| SCHEMBL21985070 | 0.80 | SLC6A2 (0.54) | SLC6A2TAAR1CYP2D6LMNATRPA1 | |
| SCHEMBL19664962 | 0.79 | TAAR1 (0.58) | SLC6A2TAAR1CYP2D6LMNATRPA1 | |
| SCHEMBL395842 | 0.78 | TAAR1 (0.52) | SLC6A2TAAR1CYP2D6LMNATRPA1 | |
| SCHEMBL1572105 | 0.78 | SLC6A2 (0.64) | SLC6A2TAAR1CYP2D6LMNATRPA1 | |
| SCHEMBL347187 | 0.78 | SLC6A2 (0.64) | SLC6A2TAAR1CYP2D6LMNATRPA1 | |
| SCHEMBL331052 | 0.78 | SLC6A2 (0.50) | SLC6A2TAAR1CYP2D6LMNATRPA1 | |
| Hydrochloric Acid SCHEMBL394411 | 0.77 | SLC6A2 (0.50) | SLC6A2TAAR1CYP2D6LMNATRPA1 | |
| SCHEMBL19827414 | 0.77 | SLC6A2 (0.50) | SLC6A2TAAR1CYP2D6LMNATRPA1 | |
| Ammonia Solution, Strong SCHEMBL10608295 | 0.76 | SLC6A2 (0.61) | SLC6A2TAAR1CYP2D6LMNATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115651017-A | Method for selectively preparing benzyl or alkyl phosphine oxide compound based on benzyl thioether derivative | 中南大学 | 2023-01-31 | — | — | CN | claimed |
| CN-115651017-A | Method for selectively preparing benzyl or alkyl phosphine oxide compound based on benzyl thioether derivative | 中南大学 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021163467-A1 | LINKING AMINO ACID SEQUENCES, MANUFACTURING METHOD THEREOF, AND USE THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-08-19 | — | — | WO | disclosed |
| US-10590145-B2 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | SHANDONG UNIVERSITY (CN) | 2020-03-17 | — | — | US | disclosed |
| WO-2011004177-A1 | FLUORESCENT POLYMERS AND METHODS FOR SOLID-PHASE EXTRACTION | TOXIMET LIMITED (GB) | 2011-01-13 | — | — | WO | disclosed |
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| US-6737544-B1 | HEATING ABOVE MELTING POINT | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-18 | — | — | US | disclosed |
| US-6639070-B1 | 4-substituted 1,3,4-oxadiazines; herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2003-10-28 | — | — | US | disclosed |
| EP-1187819-B1 | N-SUBSTITUTED PERHYDRO DIAZINE | BASF AG (DE) | 2003-07-23 | — | — | EP | disclosed |
| EP-1315733-A2 | METHOD FOR PRODUCING ANELLATED TETRAHYDRO-[1H]-TRIAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2003-06-04 | — | — | EP | disclosed |
| WO-1999005130-A1 | SUBSTITUTED 3-PHENYL ISOXAZOLINES | BASF AKTIENGESELLSCHAFT (DE) | 1999-02-04 | — | — | WO | disclosed |
| EP-0891336-A1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-20 | — | — | EP | disclosed |
| WO-1998042682-A1 | NOVEL 1-AMINO-3 BENZYL URACILS | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-01 | — | — | WO | disclosed |
| CN-1189824-A | 1-amino-3-benzyluracils | BASF AG (DE) | 1998-08-05 | — | — | CN | disclosed |
| EP-0835248-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1998-04-15 | — | — | EP | disclosed |
| US-5677322-A | THERAPY FOR AGING, DIABETES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| WO-1997035845-A1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997001543-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-01-16 | — | — | WO | disclosed |
| EP-0638075-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-15 | — | — | EP | disclosed |
| WO-1994019335-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590145-B2 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | TYMP, DPYD, TPMT | SLC6A2 822/4885TAAR1 4783/4885CYP2D6 152/4885 |
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | CBR1, CBR3, QSOX1 | SLC6A2 4298/4885TAAR1 1548/4885CYP2D6 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.